** Shares of eye-drug maker Harrow Inc HROW.O fall 24.7% to $39 premarket
** Co's Q3 revenue rose 43.8% to $49.3 mln, missing estimates of $52.8 mln as per data compiled by LSEG
** HROW's adj. earnings before interest, tax, depreciation and amortization at $8.8 mln vs estimates of $11.7 mln
** Reported qtrly. loss of 12 cents per share
** Alongside 44% Y‑o‑Y revenue growth, co achieved a modest sequential revenue increase, despite Q3's traditional summer seasonality and operational bumps that pushed some Q3 revenue into Q4 - Mark L. Baum, CEO
** Avg rating of 4 brokerages is a "buy"; median PT is $60 - LSEG data
** As of last close, stock has more than quadrupled YTD
(Reporting by Sukriti Gupta in Bengaluru)
((Sukriti.Gupta@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。